Search
Dichloroacetic acid
go.drugbank.com/drugs/DB08809ApprovedInvestigationalWithdrawnA phase 1 study in 5 patients concluded that DCA was safe, but wasn't designed to establish effectiveness. … DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market
Moxonidine
go.drugbank.com/drugs/DB09242ApprovedInvestigationalWithdrawnMoxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. … It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive.
Voxilaprevir
go.drugbank.com/drugs/DB12026ApprovedInvestigationalPrior to Vosevi, there were no approved retreatment options for patients who have previously received, and failed, a regimen containing an NS5A inhibitor for treatment of chronic HCV infection. … Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV)
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseBCG-unresponsive non-muscle invasive bladder cancer
go.drugbank.com/conditions/DBCOND0153568Synonyms: Non-muscle invasive bladder cancer ("nmibc") unresponsive/intolerant to bcgBaricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigational[L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe.
Categories: Experimental Unapproved Treatments for COVID-19Brexpiprazole
go.drugbank.com/drugs/DB09128ApprovedInvestigationalCompared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor … [L46417] Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors.
Categories: Antidepressive Agents Indicated for Depression, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeNarsoplimab
go.drugbank.com/drugs/DB16418ApprovedInvestigational[A241030] Evidence increasingly points to a role for the complement system in TMA. … [A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults
Nalbuphine
go.drugbank.com/drugs/DB00844ApprovedInvestigationalIt appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Heterocyclic Compounds with 4 or More RingsHydroxypropyl cellulose
go.drugbank.com/drugs/DB00840ApprovedIt is used to treat syndromes characterized by insufficient tear production (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis … , and as a lubricant for artificial eyes.
Categories: Compounds used in a research, industrial, or household settingOteracil
go.drugbank.com/drugs/DB03209ApprovedInvestigationalfor continued cancer growth. … Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy.
Mixtures: TS-ONE CAPSULE 20, TS-ONE CAPSULE 20